howdy vic, the novartis deal it seems was negotiated on different terms than the GSK out licence for IMP731...
Also note, the "novartis" deal was originally negotiated with Co-Stim a couple of years before Novartis took
them over......
What else is of significance that analysts reports on behalf of immutep quite often mention possibilities
of milestones from GSK but I can't remember one likewise for novartis....
OK what does that mean?...I suggest you're on the money, if Novartis on the data collation of these trials
decide it's worth progressing to further research, even stage III, there is the liklehood of a milestone
forthcoming and it may be substantial, given the time between the initial installment and now...
Off coarse if they discard it, it's zilch...But geez they've spent a lot of time and money on it...
- Forums
- ASX - By Stock
- IMM
- LAG525 Solid and Hematologic Malignancies trial completed
LAG525 Solid and Hematologic Malignancies trial completed, page-7
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $551.9M |
Open | High | Low | Value | Volume |
37.0¢ | 39.0¢ | 37.0¢ | $1.296M | 3.401M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 54900 | 37.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 22008 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 54900 | 0.375 |
5 | 90652 | 0.370 |
4 | 133026 | 0.365 |
5 | 48561 | 0.360 |
6 | 66776 | 0.355 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 22008 | 1 |
0.385 | 574526 | 4 |
0.390 | 300273 | 9 |
0.395 | 166772 | 7 |
0.400 | 268030 | 8 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online